NanoViricides to Address AMR Summit 2024 on Innovative Drug Technologies

NanoViricides, a leader in antiviral nanomedicines, announced that Dr. Anil R. Diwan will present at the Global AMR Summit 2024. The event, held at the Kimpton Marlowe Hotel in Cambridge, MA, will focus on combatting antimicrobial resistance (AMR), a significant public health threat.

Dr. Diwan will discuss the company's "Trojan Horse" technology, which targets pathogens while sparing healthy cells. This approach uses a nanoviricide platform designed to tackle AMR effectively by reducing toxicity and enhancing drug efficacy.

This innovation could play a vital role in addressing the growing antibiotic resistance market. Forecasts predict global market growth from USD 10.16 billion in 2023 to USD 27.39 billion by 2031. The company's lead drug, NV-387, has shown promise in clinical trials, exhibiting strong antiviral activity with excellent safety and tolerability.